Substance Use Disorders Clinical Trial
— POSTOfficial title:
Identifying an Effective and Cost Beneficial Approach to Preventing OUD in Justice-Involved Youth
The United States is experiencing an opioid epidemic. Sadly, opioid-related fatalities are on the rise, causing profound emotional, financial, and cultural impacts. One way to reduce these negative impacts is to prevent people from developing opioid use problems in the first place. Research shows that youth and young adults in the juvenile justice system have higher rates of opioid use disorder than other young people in the general population. The POST Study seeks develop, implement and evaluate the effectiveness and cost of 2 opioid use prevention programs of varying intensities. The prevention programs are designed specifically for youth and young adults living in justice settings. It is implemented during the time they are transitioning out of incarceration and back into the community. The research team hopes their results will help justice settings implement their own effective opioid prevention programs in the future.
Status | Recruiting |
Enrollment | 215 |
Est. completion date | August 31, 2024 |
Est. primary completion date | August 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 25 Years |
Eligibility | Inclusion Criteria: - Age 15-25 - Leaving a Washington State detention facility or group home in the next 5-7 months - Able to speak/understand English sufficiently to participate meaningfully in the intervention and assessments Exclusion Criteria: - Diagnosed with a moderate or severe Opioid Use Disorder - Has a learning or mental health issue severe enough that they are unable to participate meaningfully in the intervention and assessments (e.g. schizophrenia or severe developmental disability) |
Country | Name | City | State |
---|---|---|---|
United States | Washington State Department of Children, Youth and Families | Olympia | Washington |
Lead Sponsor | Collaborator |
---|---|
Seattle Children's Hospital | Michigan State University, National Institute on Drug Abuse (NIDA), RTI International, University of Washington, Washington State Department of Children, Youth and Families |
United States,
Abbott PJ. A review of the community reinforcement approach in the treatment of opioid dependence. J Psychoactive Drugs. 2009 Dec;41(4):379-85. Review. — View Citation
Ahrens KR, Dubois DL, Garrison M, Spencer R, Richardson LP, Lozano P. Qualitative exporation of relationships with important non-parental adults in the lives of youth in foster care. Child Youth Serv Rev. 2011 Jun 1;33(6):1012-1023. — View Citation
Almirall D, Nahum-Shani I, Sherwood NE, Murphy SA. Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research. Transl Behav Med. 2014 Sep;4(3):260-74. doi: 10.1007/s13142-014-0265-0. — View Citation
Bandura A. Social learning theory. Englewood Cliffs, NJ: Prentice Hall; 1977.
Banerjee G, Edelman EJ, Barry DT, Becker WC, Cerdá M, Crystal S, Gaither JR, Gordon AJ, Gordon KS, Kerns RD, Martins SS, Fiellin DA, Marshall BD. Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study. Addiction. 2016 Nov;111(11):2021-2031. doi: 10.1111/add.13491. Epub 2016 Aug 23. — View Citation
Carroll KM, Ball SA, Nich C, Martino S, Frankforter TL, Farentinos C, Kunkel LE, Mikulich-Gilbertson SK, Morgenstern J, Obert JL, Polcin D, Snead N, Woody GE; National Institute on Drug Abuse Clinical Trials Network. Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study. Drug Alcohol Depend. 2006 Feb 28;81(3):301-12. Epub 2005 Sep 28. — View Citation
Case A, Deaton A. Mortality and morbidity in the 21(st) century. Brookings Pap Econ Act. Spring 2017;2017:397-476. — View Citation
Catalano RF, Gainey RR, Fleming CB, Haggerty KP, Johnson NO. An experimental intervention with families of substance abusers: one-year follow-up of the focus on families project. Addiction. 1999 Feb;94(2):241-54. — View Citation
Catalano RF, Hawkins JD. The social development model: A theory of antisocial behavior. In: Hawkins JD, ed. Delinquency and crime: Current theories. New York: Cambridge University Press; 1996:149-97.
Catalano RF, Park J, Harachi TW, Haggerty KP, Abbott RD, Hawkins JD. Mediating the effects of poverty, gender, individual characteristics, and external constraints on antisocial behavior: A test of the social development model and implications for developmental life-course theory. In: Farrington DP, ed. Advances in criminological theory: Vol 14. New Brunswick, NJ: Transaction; 2005:99-123.
Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012 Jan 13;61(1):10-3. — View Citation
Charak R, Ford JD, Modrowski CA, Kerig PK. Polyvictimization, Emotion Dysregulation, Symptoms of Posttraumatic Stress Disorder, and Behavioral Health Problems among Justice-Involved Youth: a Latent Class Analysis. J Abnorm Child Psychol. 2019 Feb;47(2):287-298. doi: 10.1007/s10802-018-0431-9. — View Citation
Cheng T, Small W, Nosova E, Hogg B, Hayashi K, Kerr T, DeBeck K. Nonmedical prescription opioid use and illegal drug use: initiation trajectory and related risks among people who use illegal drugs in Vancouver, Canada. BMC Res Notes. 2018 Jan 16;11(1):35. doi: 10.1186/s13104-018-3152-9. — View Citation
Fleming C, Haggerty K. Process and Outcomes Evaluation of Keys to Success. 2013.
Fleming CB, Catalano RF, Oxford ML, Harachi TW. A test of generalizability of the social development model across gender and income groups with longitudinal data from the elementary school developmental period. Journal of Quantitative Criminology 2002;18:423-39.
Florence CS, Zhou C, Luo F, Xu L. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Med Care. 2016 Oct;54(10):901-6. doi: 10.1097/MLR.0000000000000625. — View Citation
Ford JD, Chang R, Levine J, Zhang W. Randomized clinical trial comparing affect regulation and supportive group therapies for victimization-related PTSD with incarcerated women. Behav Ther. 2013 Jun;44(2):262-76. doi: 10.1016/j.beth.2012.10.003. Epub 2012 Nov 5. — View Citation
Ford JD, Grasso DJ, Greene CA, Slivinsky M, DeViva JC. Randomized clinical trial pilot study of prolonged exposure versus present centred affect regulation therapy for PTSD and anger problems with male military combat veterans. Clin Psychol Psychother. 2018 Sep;25(5):641-649. doi: 10.1002/cpp.2194. Epub 2018 Apr 23. — View Citation
Ford JD, Grasso DJ, Hawke J, Chapman JF. Poly-victimization among juvenile justice-involved youths. Child Abuse Negl. 2013 Oct;37(10):788-800. doi: 10.1016/j.chiabu.2013.01.005. Epub 2013 Feb 19. — View Citation
Ford JD, Steinberg KL, Hawke J, Levine J, Zhang W. Randomized trial comparison of emotion regulation and relational psychotherapies for PTSD with girls involved in delinquency. J Clin Child Adolesc Psychol. 2012;41(1):27-37. doi: 10.1080/15374416.2012.632343. — View Citation
Ford JD, Steinberg KL, Zhang W. A randomized clinical trial comparing affect regulation and social problem-solving psychotherapies for mothers with victimization-related PTSD. Behav Ther. 2011 Dec;42(4):560-78. doi: 10.1016/j.beth.2010.12.005. Epub 2011 Apr 16. — View Citation
Forsyth CJ, Biggar RW, Chen J, Burstein K. Examining heroin use and prescription opioid misuse among adolescents. Criminal Justice Studies: A Critical Journal of Crime, Law & Society 2017;30:320-9.
Ghandour LA, El Sayed DS, Martins SS. Alcohol and illegal drug use behaviors and prescription opioids use: how do nonmedical and medical users compare, and does motive to use really matter? Eur Addict Res. 2013;19(4):202-10. doi: 10.1159/000345445. Epub 2013 Feb 7. — View Citation
Godley MD, Passetti LL, Subramaniam GA, Funk RR, Smith JE, Meyers RJ. Adolescent Community Reinforcement Approach implementation and treatment outcomes for youth with opioid problem use. Drug Alcohol Depend. 2017 May 1;174:9-16. doi: 10.1016/j.drugalcdep.2016.12.029. Epub 2017 Feb 22. — View Citation
Godley SH, Hedges K, Hunter B. Gender and racial differences in treatment process and outcome among participants in the adolescent community reinforcement approach. Psychol Addict Behav. 2011 Mar;25(1):143-54. doi: 10.1037/a0022179. — View Citation
Godley SH, Hunter BD, Fernández-Artamendi S, Smith JE, Meyers RJ, Godley MD. A comparison of treatment outcomes for adolescent community reinforcement approach participants with and without co-occurring problems. J Subst Abuse Treat. 2014 Apr;46(4):463-71. doi: 10.1016/j.jsat.2013.10.013. Epub 2013 Nov 11. — View Citation
Godley SH, Meyers RJ, Smith JE, et al. The Adolescent Community Reinforcement Approach for Adolescent Cannabis Users (Cannabis Youth Treatment (Cyt) Series) - Volume 4. Rockville, MD.
Godley SH, Smith JE, Meyers RJ, Godley MD. The Adolescent Community Reinforcement Approach: A Clinical Guide for Treating Substance Use Disorders. Normal, IL: Chestnut Health Systems; 2016.
Goossens I, Nicholls TL, Torchalla I, Brink J, de Ruiter C. The Perceived Impact of Trauma-Focused Research on Forensic Psychiatric Patients With Lifetime Victimization Histories. J Empir Res Hum Res Ethics. 2016 Oct;11(4):334-345. doi: 10.1177/1556264616670769. Epub 2016 Nov 25. — View Citation
Grisso T. Double jeopardy: adolescent offenders with mental disorders. Chicago: University of Chicago Press; 2004.
Henderson CE, Wevodau AL, Henderson SE, Colbourn SL, Gharagozloo L, North LW, Lotts VA. An independent replication of the Adolescent-Community Reinforcement Approach with justice-involved youth. Am J Addict. 2016 Apr;25(3):233-40. doi: 10.1111/ajad.12366. Epub 2016 Mar 18. — View Citation
Hirschi T. Causes of delinquency. Berkeley, CA: University of California Press; 1969.
Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019 Apr 1;197:78-82. doi: 10.1016/j.drugalcdep.2018.12.030. Epub 2019 Feb 14. — View Citation
Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013 Sep 1;132(1-2):95-100. doi: 10.1016/j.drugalcdep.2013.01.007. Epub 2013 Feb 12. — View Citation
Martins SS, Segura LE, Santaella-Tenorio J, Perlmutter A, Fenton MC, Cerdá M, Keyes KM, Ghandour LA, Storr CL, Hasin DS. Prescription opioid use disorder and heroin use among 12-34 year-olds in the United States from 2002 to 2014. Addict Behav. 2017 Feb;65:236-241. doi: 10.1016/j.addbeh.2016.08.033. Epub 2016 Aug 30. — View Citation
Meyers RJ, Roozen HG, Smith JE. The community reinforcement approach: an update of the evidence. Alcohol Res Health. 2011;33(4):380-8. Review. — View Citation
Mulvey EP, Schubert CA, Chassin L. Substance Use and Offending in Serious Adolescent Offenders. In: Department of Justice OoJP, Office of Juvenile Justice and Delinquency Prevention., ed. Washington, DC: U.S. 2010.
Mulvey EP. Highlights From Pathways to Desistance: A Longitudinal Study of Serious Adolescent Offenders. 2011.
Opioid epidemic. 2016. (Accessed September 25, 2018, at https://www.atg.wa.gov/opioid-epidemic.)
Opioids. 2016. (at https://www.samhsa.gov/atod/opioids.)
Pain in the nation: The drug, alcohol and suicide crises and the need for a national resilience strategy. 2017. (Accessed September 25, 2018, at http://www.paininthenation.org/assets/pdfs/TFAH-2017- PainNationRpt.pdf.)
Perez NM, Jennings WG, Baglivio MT. A path to serious, violent, chronic delinquency: The harmful aftermath of adverse childhood experiences. Crime & Delinquency 2018;64:3-25.
R.L. M. The current state of differential association theory. Crime and Delinquency 1988;34:277-306.
Roozen HG, Boulogne JJ, van Tulder MW, van den Brink W, De Jong CA, Kerkhof AJ. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug Alcohol Depend. 2004 Apr 9;74(1):1-13. Review. — View Citation
Schulenberg JE, Johnston LD, O'Malley PM, Bachman JG, Miech RA, Patrick ME. Monitoring the Future national survey results on drug use, 1975-2017: Volume II, College students and adults ages 19-55. Ann Arbor: Institute for Social Research, The University of Michigan; 2018.
Scott T, Brown SL. Risks, strengths, gender, and recidivism among justice-involved youth: A meta-analysis. J Consult Clin Psychol. 2018 Nov;86(11):931-945. doi: 10.1037/ccp0000343. — View Citation
Sung HE, Richter L, Vaughan R, Johnson PB, Thom B. Nonmedical use of prescription opioids among teenagers in the United States: trends and correlates. J Adolesc Health. 2005 Jul;37(1):44-51. — View Citation
Sutherland EH. Development of the theory [Private paper published posthumously]. In: Schuessler K, ed. Edwin Sutherland on analyzing crime. Chicago: University of Chicago Press; 1973:13-29.
The National Center for Addiction and Substance Abuse Research, Columbia University. Criminal Neglect: Substance Abuse, Juvenile Justice and The Children Left Behind. 2004.
Understanding the epidemic. Retrieved from https://www.cdc.gov/drugoverdose/epidemic/index.html. Accessed 3-2-2019.2018.
Vaughn MG, Fu Q, Perron BE, Wu LT. Risk profiles among adolescent nonmedical opioid users in the United States. Addict Behav. 2012 Aug;37(8):974-7. doi: 10.1016/j.addbeh.2012.03.015. Epub 2012 Mar 27. — View Citation
Wojciechowski TW. Developmental Trajectories of Opioid Use Among Juvenile Offenders: An Epidemiological Examination of Group Characteristics and Criminological Risk Factors. Subst Use Misuse. 2019;54(7):1203-1213. doi: 10.1080/10826084.2019.1573837. Epub 2019 Feb 15. — View Citation
www.wsipp.wa.gov/BenefitCost?topicId=1 Accessed 3-2-2019.
* Note: There are 53 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Participant attendance | Number of sessions attended | 2 months post-release (Phase I) | |
Other | Participant attendance | Number of sessions attended | 3 months post-release (Phase II) | |
Other | Participant satisfaction | Self-reported satisfaction with coach on a scale of very satisfied, somewhat satisfied, not very satisfied, not at all satisfied | 2 months post-release (Phase I) | |
Other | Participant satisfaction | Self-reported satisfaction with coach on a scale of very satisfied, somewhat satisfied, not very satisfied, not at all satisfied | 3 months post-release (Phase II) | |
Primary | Number of substance use episodes | Self-reported number of episodes of substance use on days any substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 2 months post-release (Phase I) | |
Primary | Number of substance use episodes | Self-reported number of episodes of substance use on days any substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 3 months post-release (Phase II) | |
Primary | Number of substance use episodes | Self-reported number of episodes of substance use on days any substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 6 months post-release (Phase II) | |
Primary | Frequency of substance use episodes | Self-reported number of days of any substance use in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 2 months post-release (Phase I) | |
Primary | Frequency of substance use episodes | Self-reported number of days of any substance use in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 3 months post-release (Phase II) | |
Primary | Frequency of substance use episodes | Self-reported number of days of any substance use in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 6 months post-release (Phase II) | |
Primary | Rate of Recidivism | Convictions in either the juvenile or adult justice system for offenses within an 18-month period | 12 months post-release | |
Primary | Rate of Recidivism | Convictions in either the juvenile or adult justice system for offenses within an 18-month period | 18 months post-release | |
Secondary | Number of new opioid users | Number of participants who ever used opioids among those who had never used at baseline based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | 6 months post-release (Phase II) | |
Secondary | Number of participants with escalated opioid use | Number of participants whose days of use increased compared to prior measure based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 2 months post-release vs. before incarceration (Phase I) | |
Secondary | Number of participants with escalated opioid use | Number of participants whose days of use increased compared to prior measure based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 3 months post-release vs. before incarceration (Phase II) | |
Secondary | Number of participants with escalated opioid use | Number of participants whose days of use increased compared to prior measure based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 6 months post-release vs. at 3 months post-release (Phase II) | |
Secondary | Number of use episodes of specific substances (e.g. opioids, marijuana, etc.) | Self-reported number of episodes of use of a specific substance on days that substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 2 months post-release (Phase I) | |
Secondary | Number of use episodes of specific substances (e.g. opioids, marijuana, etc.) | Self-reported number of episodes of use of a specific substance on days that substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 3 months post-release (Phase II) | |
Secondary | Number of use episodes of specific substances (e.g. opioids, marijuana, etc.) | Self-reported number of episodes of use of a specific substance on days that substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 6 months post-release (Phase II) | |
Secondary | Frequency of use of specific substances (e.g. opioids, marijuana, etc.) | Self-reported number of days a specific substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 2 months post-release (Phase I) | |
Secondary | Frequency of use of specific substances (e.g. opioids, marijuana, etc.) | Self-reported number of days a specific substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 3 months post-release (Phase II) | |
Secondary | Frequency of use of specific substances (e.g. opioids, marijuana, etc.) | Self-reported number of days a specific substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees. | Last 30 days at 6 months post-release (Phase II) | |
Secondary | Number of instances of overdose among non-opioid users | Self-reported number of instances of overdose | Last 30 days at 3 months post-release (Phase II) | |
Secondary | Number of instances of overdose among non-opioid users | Self-reported number of instances of overdose | Last 30 days at 6 months post-release (Phase II) | |
Secondary | Problematic substance use | Self-reported substance use beyond a developmentally appropriate threshhold. For those under age 21, problematic use is defined as any of the following: 1) use of alcohol or marijuana several times a week or more; 2) use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) score on CRAFFT of 2 or more (https://crafft.org).
For those age 21 and older, problematic use is defined as any of the following: 1) use of alcohol or marijuana every day or most days each week; 2) use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) score on CRAFFT of 2 or more (https://crafft.org) |
Last 30 days at 6 months post-release (Phase II) | |
Secondary | Problematic substance use | Self-reported substance use beyond a developmentally appropriate threshhold. For those under age 21, problematic use is defined as any of the following: 1) use of alcohol or marijuana several times a week or more; 2) use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) score on CRAFFT of 2 or more (https://crafft.org).
For those age 21 and older, problematic use is defined as any of the following: 1) Use of alcohol or marijuana every day or most days each week; 2) Use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) Score on CRAFFT of 2 or more (https://crafft.org) |
Last 30 days at 3 months post-release (Phase II) | |
Secondary | Cost of ACRA Lite (medium intensity arm) per participant | Cost in US Dollars of ACRA Lite intervention from study's Cost Analysis program | 3 months post-release | |
Secondary | Cost of Enhanced ACRA (high intensity arm) per participant | Cost in US Dollars of Enhanced ACRA intervention from study's Cost Analysis program | 3 months post-release | |
Secondary | Cost of Education Workbook (low intensity arm) per participant | Cost in US Dollars of Education Workbook intervention from study's Cost Analysis program | at release |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05660434 -
Using Aromatherapy in Substance Use Disorder
|
N/A | |
Active, not recruiting |
NCT05338268 -
Substance Use and Loneliness
|
N/A | |
Completed |
NCT04098614 -
Barriers to Substance Use Disorder Recovery
|
N/A | |
Completed |
NCT03954184 -
E-health Implementation (Iowa)
|
N/A | |
Completed |
NCT03590106 -
Cardiac Surgery Peer Recovery Support Program
|
N/A | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Recruiting |
NCT06273228 -
Parenting Young Children in Pediatrics
|
N/A | |
Recruiting |
NCT05327504 -
Written Exposure Therapy for Veterans With SUD and PTSD
|
N/A | |
Terminated |
NCT03517111 -
The Impact of a Parenting Intervention on Latino Youth Health Behaviors
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT04401215 -
Technologically-Augmented Referrals to Mitigate Addiction Consequences
|
N/A | |
Not yet recruiting |
NCT06187701 -
Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients
|
N/A | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
Active, not recruiting |
NCT02382042 -
Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans
|
N/A | |
Completed |
NCT01237366 -
Study Targeting Affect Regulation
|
Phase 1/Phase 2 | |
Terminated |
NCT01356667 -
Drum-Assisted Therapy for Native Americans
|
N/A | |
Completed |
NCT00708890 -
Twelve Step Based Self-help Groups for Substance Related Disorders
|
N/A | |
Active, not recruiting |
NCT04048850 -
Zepatier in Patients With Substance Use
|
||
Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 |